Dr Lal PathLabs Ltd. is India’s leading diagnostic laboratory and pathology services provider. It was established in 1949 by Dr S.K. Lal and is headquartered in New Delhi. The company operates a network of over 2000 collection centers and more than 200 laboratories and provides services in over 300 cities and towns across India.
The company offers a wide range of clinical laboratory tests and services, including biochemical tests, immunological tests, microbiology tests, hematology tests, histopathology tests, cytology tests, and molecular diagnostics tests. It also provides a variety of preventive health checkup packages.
Dr Lal PathLabs has a strong presence in the online space and offers services such as online booking and test results, online payment, and home sample collection. The company is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
| Promoters + | 55.01% | 54.61% | 54.60% | 54.60% | 54.60% |
| FIIs + | 23.27% | 24.35% | 25.36% | 26.15% | 25.43% |
| DIIs + | 8.34% | 8.85% | 9.27% | 9.40% | 12.42% |
| Government + | 0.29% | 0.29% | 0.29% | 0.29% | 0.29% |
| Public + | 12.65% | 11.48% | 10.12% | 9.24% | 6.95% |
| Others + | 0.44% | 0.41% | 0.37% | 0.32% | 0.30% |
| No. of Shareholders | 1,74,444 | 1,60,679 | 1,49,901 | 1,46,741 | 1,31,189 |
The shareholding patterns of Dr. Lal Pathlabs have shown notable trends from June 2023 to June 2024. The promoters’ stake remained relatively stable, decreasing slightly from 55.01% in June 2023 to 54.60% by March 2024, and maintaining this level through June 2024.
Foreign Institutional Investors (FIIs) have shown a positive trajectory, increasing their stake from 23.27% in June 2023 to 25.43% in June 2024, indicating growing confidence in Dr. Lal Pathlabs among international investors. Domestic Institutional Investors (DIIs) also exhibited a significant rise in their holdings, climbing from 8.34% in June 2023 to 12.42% by June 2024, reflecting a strengthening institutional interest in the company.
In contrast, the public shareholding has seen a decline from 12.65% in June 2023 to 6.95% in June 2024, suggesting a shift away from retail investors. Government holdings remained constant at 0.29%, while other shareholders showed a slight decrease.
Overall, the changing shareholding dynamics highlight a growing institutional interest in Dr. Lal Pathlabs, particularly from FIIs and DIIs, which may contribute positively to the company’s market perception and stability moving forward.
You can buy shares of Dr Lal PathLabs on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). You can buy shares through a stockbroker or an online trading platform.
To buy shares of Dr Lal PathLabs through a stockbroker, you must open a Demat and trading account with the stockbroker. You will have to fill out an account opening form, provide KYC documents, and submit the form with the required fees. Once you have opened the account, you can place an order to buy the shares of Dr Lal PathLabs.
Some online platforms to buy Lal PathLabs Stock are Zerodha, Upstox, 5Paisa, HDFC Securities, Angel Broking, ICICI Direct, Kotak Securities, etc.
| When | Maximum Price | Minimum Price |
| October 2024 | 3,410.15 | 2,965.35 |
| November 2024 | 3,546.56 | 3,083.97 |
| December 2024 | 3,582.03 | 3,114.81 |
In 2024, Dr. Lal Pathlabs is expected to reach a maximum price of ₹3,410.15 and a minimum price of ₹2,965.35 in October. As the year progresses into November, the maximum price is projected to rise to ₹3,546.56, with a minimum price of ₹3,083.97. By December, Dr. Lal Pathlabs is anticipated to achieve a maximum price of ₹3,582.03 and a minimum price of ₹3,114.81. This outlook reflects the company’s potential growth and market performance as the year unfolds.
| When | Maximum Price | Minimum Price |
| January 2025 | 3,617.85 | 2,782.96 |
| February 2025 | 3,654.39 | 2,811.07 |
| March 2025 | 3,731.13 | 2,870.10 |
| April 2025 | 3,694.19 | 2,841.68 |
| May 2025 | 3,586.59 | 2,758.92 |
| June 2025 | 3,747.99 | 2,883.07 |
| July 2025 | 3,674.50 | 2,826.54 |
| August 2025 | 3,788.14 | 2,913.96 |
| September 2025 | 3,833.60 | 2,948.92 |
| October 2025 | 3,933.27 | 3,025.60 |
| November 2025 | 4,031.61 | 3,101.24 |
| December 2025 | 4,213.03 | 3,240.79 |
In 2025, Dr. Lal Pathlabs expected to see its share prices range from a maximum of ₹3,617.85 to a minimum of ₹2,782.96 in January. By December, prices are projected to reach a maximum of ₹4,213.03 and a minimum of ₹3,240.79, demonstrating a strong upward trend throughout the year.
| When | Maximum Price | Minimum Price |
| January 2026 | 4,339.42 | 3,338.02 |
| February 2026 | 4,230.93 | 3,254.56 |
| March 2026 | 4,315.55 | 3,319.66 |
| April 2026 | 4,403.63 | 3,387.40 |
| May 2026 | 4,360.03 | 3,353.87 |
| June 2026 | 4,469.03 | 3,437.71 |
| July 2026 | 4,381.40 | 3,370.31 |
| August 2026 | 4,516.91 | 3,474.54 |
| September 2026 | 4,607.24 | 3,544.03 |
| October 2026 | 4,727.03 | 3,636.18 |
| November 2026 | 4,845.21 | 3,727.08 |
| December 2026 | 4,966.34 | 3,820.26 |
| When | Maximum Price | Minimum Price |
| January 2027 | 5,016.00 | 3,858.46 |
| February 2027 | 5,144.62 | 3,957.40 |
| March 2027 | 5,345.26 | 4,111.74 |
| April 2027 | 5,240.45 | 4,031.11 |
| May 2027 | 5,087.81 | 3,913.70 |
| June 2027 | 5,316.76 | 4,089.82 |
| July 2027 | 5,212.51 | 4,009.63 |
| August 2027 | 5,373.73 | 4,133.64 |
| September 2027 | 5,561.81 | 4,278.31 |
| October 2027 | 5,706.41 | 4,389.55 |
| November 2027 | 5,849.07 | 4,499.29 |
| December 2027 | 5,995.30 | 4,611.77 |
| When | Maximum Price | Minimum Price |
| January 2028 | 6,115.21 | 4,704.01 |
| February 2028 | 6,272.01 | 4,824.62 |
| March 2028 | 6,516.62 | 5,012.78 |
| April 2028 | 6,388.84 | 4,914.49 |
| May 2028 | 6,202.76 | 4,771.35 |
| June 2028 | 6,481.88 | 4,986.06 |
| July 2028 | 6,354.78 | 4,888.30 |
| August 2028 | 6,551.32 | 5,039.48 |
| September 2028 | 6,780.62 | 5,215.86 |
| October 2028 | 6,956.92 | 5,351.47 |
| November 2028 | 7,130.84 | 5,485.26 |
| December 2028 | 7,309.11 | 5,622.39 |
| When | Maximum Price | Minimum Price |
| January 2029 | 7,455.29 | 5,734.84 |
| February 2029 | 7,646.45 | 5,881.89 |
| March 2029 | 7,944.67 | 6,111.28 |
| April 2029 | 7,788.89 | 5,991.45 |
| May 2029 | 7,562.03 | 5,816.94 |
| June 2029 | 7,902.32 | 6,078.71 |
| July 2029 | 7,747.37 | 5,959.52 |
| August 2029 | 7,986.98 | 6,143.83 |
| September 2029 | 8,266.52 | 6,358.86 |
| October 2029 | 8,481.45 | 6,524.20 |
| November 2029 | 8,693.49 | 6,687.30 |
| December 2029 | 8,910.83 | 6,854.48 |
| When | Maximum Price | Minimum Price |
| January 2030 | 9,089.04 | 6,991.57 |
| February 2030 | 9,322.10 | 7,170.84 |
| March 2030 | 9,685.66 | 7,450.51 |
| April 2030 | 9,495.74 | 7,304.42 |
| May 2030 | 9,219.17 | 7,091.67 |
| June 2030 | 9,634.03 | 7,410.79 |
| July 2030 | 9,445.13 | 7,265.48 |
| August 2030 | 9,737.25 | 7,490.19 |
| September 2030 | 10,078.05 | 7,752.35 |
| October 2030 | 10,340.08 | 7,953.91 |
| November 2030 | 10,598.58 | 8,152.75 |
| December 2030 | 10,863.54 | 8,356.57 |
In 2030, Dr. Lal Pathlabs is projected to experience a maximum share price of ₹9,089.04 and a minimum of ₹6,991.57 in January. By December, these prices are expected to rise to a maximum of ₹10,863.54 and a minimum of ₹8,356.57, reflecting significant growth throughout the year.
Lal PathLabs Financial Condition: Last 5 years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,288 |
| Expenses + | 987 | 1,145 | 1,526 | 1,527 | 1,617 | 1,654 |
| Operating Profit | 344 | 436 | 561 | 490 | 609 | 633 |
| OPM % | 26% | 28% | 27% | 24% | 27% | 28% |
| Other Income + | 55 | 51 | 52 | 42 | 69 | 75 |
| Interest | 15 | 16 | 30 | 38 | 29 | 27 |
| Depreciation | 73 | 77 | 108 | 150 | 144 | 143 |
| Profit before tax | 310 | 394 | 475 | 344 | 505 | 538 |
| Tax % | 27% | 25% | 26% | 30% | 28% | |
| Net Profit + | 228 | 296 | 350 | 241 | 362 | 386 |
| EPS in Rs | 27.11 | 34.99 | 41.37 | 28.65 | 42.85 | 45.7 |
| Dividend Payout % | 44% | 57% | 29% | 21% | 42% |
Dr. Lal Pathlabs has exhibited a positive trend in its financial performance over the past few years, with significant growth in sales, operating profit, and net profit.
Sales and Revenue
- Sales increased from ₹1,330 crores in March 2020 to ₹2,288 crores in the trailing twelve months (TTM). Although there was a slight decline to ₹2,017 crores in March 2023, sales rebounded to ₹2,227 crores by March 2024.
Expenses
- Expenses rose from ₹987 crores in March 2020 to ₹1,654 crores in the TTM. This reflects the company’s ongoing investments and scaling operations.
Profitability
- Operating Profit fluctuated, peaking at ₹561 crores in March 2022 before declining to ₹490 crores in March 2023. However, it improved to ₹609 crores by March 2024, with TTM operating profit at ₹633 crores.
- Operating Profit Margin (OPM) has remained stable, showing an increase from 24% in March 2023 to 28% in the TTM.
Other Income and Profitability Metrics
- Other Income contributed positively, increasing from ₹55 crores in March 2020 to ₹75 crores in the TTM.
- Profit Before Tax rose from ₹310 crores in March 2020 to ₹538 crores in the TTM, with the tax rate averaging around 27-28%.
- Net Profit increased from ₹228 crores in March 2020 to ₹386 crores in the TTM, with a notable jump from ₹362 crores in March 2024.
- Earnings Per Share (EPS) rose from ₹27.11 in March 2020 to ₹45.7 in the TTM.
Dividend Payout
- Dividend Payout Percentage has varied, reaching a low of 21% in March 2023 before increasing to 42% in March 2024, balancing growth investments and shareholder rewards.
FAQs
Will Lal PathLabs Stock price grow in 2024?
The stock price of Dr. Lal PathLabs in 2024 is subject to fluctuations, with projected price targets ranging from ₹2,965.35 to ₹3,582.03.
What is the market cap of Dr Lal PathLabs?
As of September 30th, 2024, the market capitalization of Dr Lal PathLabs is ₹27,572 Cr.
What future is anticipated for Dr Lal PathLabs in 2025?
In 2025, Dr. Lal PathLabs is anticipated to experience fluctuations in its stock price, with the potential for both highs and lows throughout the year, including a maximum price target of ₹4,213.03 in December.
The share price target for Dr. Lal PathLabs in 2030 indicates substantial growth potential, with the maximum price projected to be ₹10,863.54, suggesting a positive long-term trajectory.
Also Read
In conclusion, Dr. Lal PathLabs Ltd. has established itself as India’s leading diagnostic laboratory provider, showcasing a robust growth trajectory with over 2,000 collection centers and 200 laboratories. The company’s financial performance over the past five years highlights a consistent increase in sales and operating profit, along with improved efficiency and a steady operating profit margin. With a stable promoter stake and rising institutional investments, particularly from domestic institutional investors, market confidence in the company’s prospects is evident. Projected share price targets suggest substantial growth potential, with expectations of reaching a maximum price of ₹10,863.54 by December 2030. Given its strong fundamentals, increasing demand for diagnostic services, and established reputation, Dr. Lal PathLabs presents a compelling investment opportunity in the Indian equity market.
Linkedin
